Thursday, August 17, 2017 -- New research finds that high-dose vitamin C can genetically 'reprogram' leukemic cells to mature and die normally, instead of replicating to cause cancer.
Thursday, August 17, 2017 -- (Reuters) - The U.S. Food and Drug Administration (FDA) said on Thursday it approved Pfizer Inc's rare blood cancer drug, Besponsa, with a boxed warning.
Tuesday, August 15, 2017 -- Venetoclax is the first BCL2 inhibitor to enter routine clinical practice. It is an orally bioavailable small molecule that binds BCL2 very specifically. Acting as a pharmacologic mimic of the proteins that initiate apoptosis (a so-called BH3 mimetic), venetoclax rapidly induces apoptosis in chronic lymphocytic leukemia (CLL) cells, which express high levels of BCL2 and rely on it to maintain their survival. As a single agent, daily venetoclax treatment induced durable responses in 79% of patients with relapsed or refractory CLL or small lymphocytic lymphoma in a phase I study, including complete remissions in 20% of patients. Its use was approved by the FDA in April 2016 for patients with previously treated del(17p) CLL on the basis of a
Monday, August 14, 2017 -- The regimen devised by UCLA researchers has proven to kill cancer cells and eradicate acute lymphoblastic leukemia in mouse models.
Tuesday, August 15, 2017 -- The US Food and Drug Administration (FDA) has granted orphan drug designation for H3 Biomedicine's H3B-8800, its lead clinical compound for the treatment of patients with Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML).
Wednesday, August 16, 2017 -- Enthusiasm for the CAR T cell approach may redirect rather than augment other possibly safer, more effective, evolutionarily informed approaches to cancer therapy.
Monday, August 14, 2017 -- Get the most up-to-date treatment regimens for adult T-cell leukemia/lymphoma (a non-Hodgin leukemia), such as zidovudine + alpha-interferon.
Sunday, August 13, 2017 -- A protein found in the edible mushroom commonly known as "shaggy ink cap" has the potential to kill leukemia T cells, a new study suggests.